

CORPORATE PROFILE

Kannalife, Inc. is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.


The Company's family of proprietary molecules focuses on treating oxidative stress-related and neurodegenerative diseases. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

Pennsylvania Biotechnology Center
3805 Old Easton Road
Doylestown, PA 18902
Phone: (215) 695-6559
Fax: (516) 960-9212
<https://www.kannalife.com>
info@kannalife.com

Investor Relations Firm
CORE IR
377 Oak Street
Garden City, NY 11530
(516) 222-2285
www.coreir.com
Contact: John Marco
Johnm@coreir.com

STOCK PERFORMANCE

Symbol	KLFE
Exchange	OTCQB
Market Cap.	94.27m
52 Week Range	1.01 - 6.90
Close	1.09
Volume	11
Shares Outstanding	74,225,141
As of Feb 14, 2020 3:57 pm	



MANAGEMENT TEAM

Dean Petkanas - Chairman & CEO

William A. Kinney, PhD - Chief Scientific Officer

Thoma Kikis - Chief Communications Officer, Board Director

Mark Corrao - Chief Financial Officer

BOARD OF DIRECTORS

Dean Petkanas - Chairman & CEO

Blake Schroeder - Board Director

Thoma Kikis - Founder / Chief Communications Officer, Board Director

Robert Malasek - Board Director

Timothy Scott, PhD - Board Director

RECENT HEADLINES

[Feb 11, 2020 - Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN](#)

[Aug 14, 2019 - Form CT ORDER](#)

INVESTMENT HIGHLIGHTS

We have made significant improvements in the chemistry, efficacy, and safety of CBD-like molecules. KLS-13019 is up to 200X more potent, 10X more bioavailable, 5X safer and 1000 times more effective than CBD.

-Received US Patent 9,611,213 (April 2017) "Novel Functionalized 1,3 Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy"

-Received NIH/NIDA Grant #1R41DA044898 (December 2017) on the Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy (CIPN) and drug dependence

-Received US Patent 10,004,722 (June 2018) "Method for Treating Hepatic Encephalopathy or a Disease Associated with Free Radical Mediate Stress and Oxidative Stress with Novel Functionalized 1,3- Benzene Diols"

-Article Published in The Journal of Neuroscience [Springer] (August 2018) "Pharmacology Comparisons Between Cannabidiol and KLS- 13019 "

GROWTH STRATEGY

Kannalife is a pioneer in the emerging Cannabinoid Therapeutics market to reach \$20B by 2020*